Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Stocks mentioned in the article
ChangeLast1st jan.
SANOFI 0.74% 66.37 Delayed Quote.-9.72%
SANOFI 0.88% 66.44 Real-time Quote.-8.32%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
04/25SANOFI : FDA accepts for review Supplemental Biologics License Application for 0..
PR
04/25SANOFI : Meditope Receives BioLabs Golden Ticket Award From Sanofi to Advance Bi..
AQ
04/25SANOFI : Boehringer's operating income up 20.7 percent on Sanofi deal
RE
04/25SANOFI : More Than 25 Data Presentations from Sanofi Genzyme's Multiple Sclerosi..
AQ
04/24SANOFI SA : quaterly earnings release
04/24BAM : Ex-President Aquino couldn't have foreseen Dengvaxia's unintended effects
AQ
04/24SANOFI : UK bans Sanofi epilepsy drug without pregnancy prevention plan
AQ
04/24SANOFI'S VALPROATE RESTRICTED FOR SO : Regulator
DJ
04/24SANOFI : UK bans Sanofi epilepsy drug without pregnancy prevention plan
RE
04/24BIOCENTURY - MANAGEMENT TRACKS : Probiodrug, Alder
AQ
More news
News from SeekingAlpha
04/25FDA accepts Sanofi Pasteur's marketing application for expanded use of flu va.. 
04/24Sanofi R&D chief to retire in late June 
04/23MANNKIND : Experts In Pulling Numbers From Orifices 
04/20PORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
04/20Now See Wall Street's 38 'Safer' International Dividend WallStars For April 
Financials (€)
Sales 2018 35 082 M
EBIT 2018 8 618 M
Net income 2018 4 901 M
Debt 2018 14 450 M
Yield 2018 4,67%
P/E ratio 2018 16,30
P/E ratio 2019 14,41
EV / Sales 2018 2,75x
EV / Sales 2019 2,58x
Capitalization 82 174 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 79,1 €
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-8.32%100 051
JOHNSON & JOHNSON-9.28%338 522
PFIZER2.32%220 455
NOVARTIS-8.69%202 567
ROCHE HOLDING LTD.-11.08%193 904
MERCK AND COMPANY5.97%161 967